Single and Repeated Dose Escalation Study of GSK2838232

NCT02795754 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: GSK2838232 PIB
DRUG: GSK2838232 IR1
DRUG: GSK2838232 IR2
DRUG: Placebo PIB
DRUG: Ritonavir

Sponsor

GlaxoSmithKline